Tarsus Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$51.87(as of Sep 11, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Tarsus Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$51.87
Ticker SymbolTARS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees323
CountyUSA
Market Cap$2,293.5M

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals Inc In Our Stock Scanner

As of Sep 12, 2025
As of ---
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.